Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $3.7 billion.

  • Takeda Pharmaceutical's Other Non-Current Liabilities rose 65.75% to $3.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 billion, marking a year-over-year increase of 65.75%. This contributed to the annual value of $3.5 billion for FY2025, which is 52362.3% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Other Non-Current Liabilities stood at $3.7 billion, which was up 65.75% from $3.7 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Other Non-Current Liabilities high stood at $4.6 billion for Q3 2023, and its period low was $366.1 million during Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $3.6 billion (2022), whereas its average is $3.0 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Other Non-Current Liabilities plummeted by 2535.88% in 2024, and later skyrocketed by 53984.19% in 2025.
  • Takeda Pharmaceutical's Other Non-Current Liabilities (Quarter) stood at $3.7 billion in 2021, then decreased by 9.67% to $3.3 billion in 2022, then fell by 2.55% to $3.3 billion in 2023, then increased by 13.14% to $3.7 billion in 2024, then grew by 0.66% to $3.7 billion in 2025.
  • Its Other Non-Current Liabilities was $3.7 billion in Q4 2025, compared to $3.7 billion in Q3 2025 and $3.5 billion in Q2 2025.